Asston Pharmaceuticals IPO opens for subscription with decent GMP. Check details
Asston Pharmaceuticals' IPO has opened for subscription. The price is between Rs 115 to Rs 123 per share. The IPO aims to raise Rs 27.56 crore. It has stirred moderate grey market interest. The offer will close on July 11. Allotment finalization i...
By ETMarkets.com |
ANI
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, opened for public subscription today. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO seeks to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares.
The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16.
Retail investors are required to apply for a minimum of 2,000 shares.
The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market maker.
Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and sachets.
The company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols.
The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses.
Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal.
The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
The IPO has stirred moderate interest in the grey market, where it is commanding a GMP of Rs 15 over the upper issue price of Rs 123 -- a 12% premium. The offer will close on July 11, and the allotment is expected to be finalized on July 14. The stock is scheduled to list on the BSE SME platform on July 16.
Retail investors are required to apply for a minimum of 2,000 shares.
The lead manager to the issue is Sobhagya Capital Options, while Maashitla Securities is the registrar. JSK Securities and Services will act as the market maker.
Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and sachets.
The company caters to multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and operate under rigorous quality management protocols.
ADVERTISEMENT
The IPO proceeds are intended to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital needs (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses.
Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% jump in profit after tax compared to the previous fiscal.
The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
ADVERTISEMENT
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
